'김갑성' 기자의 전체기사
-
GENPRIME ACCELERATES GLOBAL GROWTH WITH FERTILITY CENTRE LA…
The Singapore and New York-headquartered network of clinics expands its Southeast Asia presence, addressing global family-building challenges with technology and empathy NEW YORK, Nov. 20, 2025 -- Rhea Fertility, the reproductive health platform headquartered in Singapore and New York, announces the expansion of GenPrime, its clinic network, with the opening of two flagship fertility centres in Singapore and Manila, the Philippines. The launches mark a major step in scaling GenPrime's next-generation model of fertility care in Southeast Asia, helping couples and individuals pur
- 김갑성 기자
- 2025-11-20 22:00
-
ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advanc…
BRISBANE, Calif., Nov. 20, 2025 -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for Regenerative Medicine (CIRM), and has recently reached a key program milestone, having identified a lead compound that meets key development criteria. This funding will further support the advancement of ReviR Therapeutics' HTT-PMS1 genetic medicine program, whereby a small molecule selectively reduces the mRNA of two genes implicated in both the cause and progres
- 김갑성 기자
- 2025-11-20 22:00
-
Kolmar Korea Named Among TIME's World's Best Companies…
Ranked in the Top 7% Among More Than 4,000 Global Corporations, Highlighting Leadership in Eco-Friendly Innovation and Responsible Growth SEOUL, South Korea, Nov. 20, 2025 -- Kolmar Korea, a global cosmetics ODM leader, has been selected for the second consecutive year to TIME's World's Best Companies in Sustainable Growth 2026, reaffirming its position as a global front-runner in eco-friendly and responsible business practices. The rankings were announced on November 13 by TIME in collaboration with global research firm Statista, recognizing the top 500 companies worldwide for
- 김갑성 기자
- 2025-11-20 21:30
-
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Th…
[ 메디채널 김갑성 기자 ] The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 clinical trial, significantly reducing recurrence risk and improving cure rates. No immunotherapy has been approved globally for gastric cancer perioperative treatment – HANSIZHUANG is poised to address this unmet medical need. SHANGHAI, Nov. 20, 2025 -- Shanghai Henlius Biotech,
- 김갑성 기자
- 2025-11-20 18:52
-
Clarity Eye Centre Brings SILK™ Laser Eye Technology to Hon…
HONG KONG, Nov. 20, 2025 -- Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that powers SILK™ (Smooth Incision Lenticule Keratomileusis), ushering in a new era of precision and gentle laser vision correction for myopia, with or without astigmatism.[1] SILK™: A Revolutionary Leap in Refractive Surgery SILK™ represents a groundbreaking advancement in vision
- 김갑성 기자
- 2025-11-20 17:34
-
Gong Yingying: The Next Era of AI Healthcare Requires Trust…
KUALA LUMPUR, Malaysia, Nov. 20, 2025 -- At the 2025 Fortune Innovation Forum in Kuala Lumpur, global industry leaders and innovators gathered to explore the technologies transforming healthcare. Speaking at the featured roundtable "AI vs. MD," Ms. Gong Yingying, Founder and Chairwoman of Yidu Tech, shared her perspective on the responsible development of AI in healthcare. She was joined by KPJ Healthcare Berhad President & Managing Director Mr. Keat Chyuan Chin and NUHS Clinical Advisory Director Dr. Zubin Daruwalla, with Fortune AI Editor Jeremy Kahn moderating.
- 김갑성 기자
- 2025-11-20 16:52
-
KHB, MEDICA 2025에서 자동 화학발광 면역분석기 Polaris V150 선보여
[ 메디채널 김갑성 기자 ] 시안, 중국 2025년 11월 20일 -- 글로벌 체외진단(IVD) 솔루션 공급업체 상하이 케후아 바이오엔지니어링(Shanghai Kehua Bio-engineering Co., Ltd., KHB)이 세계적 의료 산업 전시회인 MEDICA 2025에서 최신 소형 화학발광 플랫폼 Polaris V150 자동 화학발광 면역분석기를 선보였다. 올해 KHB 부스의 핵심 전시 제품인 Polaris V150은 자동화 진단 분야에서 이룬 지속적인 혁신을 보여준다. 중소 규모 실험실은 물론 대형 병원과 외부 독립 검사기관의 STAT 및 응급 검사를 지원하도록 설계된 Polaris V150은 효율성과 정밀성, 사용 편의성을 하나의 탁상형 장비에 집약했다. 0.36m²의 설치 공간에 내장형 터치스크린과 컴팩트한 설계로 외부 장치 없이도 실험실에서 강력한 면역분석 기능을 제공한다. 작은 설치 공간과 효율적인 워크플로 0.36m²의 좁은 설치 면적에도 Polaris V150은 시간당 150건의 검사를 처리해 제한된 환경에서도 실험실이 효율적으로 운영될 수 있도록 한다. 시료•시
- 김갑성 기자
- 2025-11-20 15:23
-
Smartee Deepens Its Strategy for Central Asia and Russia in 2…
SHANGHAI, Nov. 20, 2025 -- Smartee Denti-Technology is reinforcing its international footprint with a focused strategy in Central Asia and Russia for 2025, cementing its position as a global leader in clear aligner and digital orthodontic technologies. This year, Smartee showcased its innovative orthodontic solutions at major regional exhibitions, including Dental Salon Moscow (April), Kazdent Expo Almaty and IDECA Tashkent (May), and Dental Expo Moscow and CADEX Almaty (September–October). These events underscored Smartee's expertise in digital orthodontics, highlighting its commitmen
- 김갑성 기자
- 2025-11-20 13:53
-
Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial O…
Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed Adoption of Remplir™ among Australian urologists is accelerating, with ~100 surgeries conducted by surgeons nationwide. This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company. Despite advances such as nerve-sparing techniques and robotic-assisted radical prostatectomy (RARP), damage to the peripheral
- 김갑성 기자
- 2025-11-20 13:52
-
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clin…
SHANGHAI and HONG KONG, Nov. 20, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will present the latest data and future plans for three mid/late-stage clinical programs, including ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), ATG-037 (oral CD73 small mo
- 김갑성 기자
- 2025-11-20 10:56
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-31_SAT
- 도코모, 아두나와 글로벌 네트워크 API 확장을 위한 파트너십 계약 체결 23:19
- JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL 20:58
- Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery" 16:15
- CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK 12:05
- Origin Agritech Announces Fiscal Year 2025 Results 06:00
- White Pearl Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering 05:47
- Planet Green Holdings Corp. Provides Response to Unusual Market Action 05:05
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 02월 01일 00시 50분